➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Mallinckrodt
Express Scripts
AstraZeneca
Moodys

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

Claims for Patent: 4,746,508

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 4,746,508
Title: Drug administration
Abstract:Compositions and methods useful for the prevention or treatment of a human or animal disorder or for the regulation of a human or animal physiological condition are provided. The compositions used comprise, in admixture, a biologically-effective amount of a drug specific for the disorder or condition and a biocompatible, water-soluble, amphiphilic steroid, other than a natural bile salt, which is capable of increasing drug permeability of the human or animal body surface across which the drug is to be administered, in an amount effective to increase the permeability of the surface to the drug.
Inventor(s): Carey; Martin C. (Wellesley, MA), Moses; Alan C. (Waban, MA), Flier; Jeffrey S. (West Newton, MA)
Assignee: Beth Israel Hospital Assn. (Boston, MA) The Brigham and Womens Hospital, Inc. (Boston, MA)
Application Number:06/614,115
Patent Claims:1. A composition useful for the prevention or treatment of a human or animal disorder or for the regulation of a human or animal physiological condition comprising, in admixture;

as an active ingredient, a biologically-effective amount of a peptide specific for the particular disorder or condition; and

(b) as an adjuvant, a biocompatible, water-soluble, fusidic acid derivative which has the formula: ##STR3## wherein a dashed line represents a single or a double bond; D represents a group having a molecular weight below about 600 daltons which renders an effective amount of said steroid water-soluble within a range of about pH 2 to about pH 12;

E and G each represent OAc, OH, a lower alkyl group or a lower heteroalkyl group;

W represents OAc or H; and

Q, V and X each represent H or OH, said steroid containing from two to three polar functions, exclusive of the function represented by D; said adjuvant being capable of increasing peptide permeability of a human or animal mucosal surface across which the peptide is to be administered, in an amount effective to increase the permeability of said mucosal surface to said peptide.

2. The composition of claim 1 wherein said fusidic acid derivative has the formula: ##STR4## wherein a dashed line represents a single or a double bond; D represents a group having a molecular weight below about 600 daltons which renders an effective amount of said steroid water soluble within a range of about pH 2 to about pH 12;

E represents .beta. OAc, .alpha. OH, a lower alkyl group in .beta. position, or a lower heteroalkyl group in .beta. position;

G represents .alpha. OAc, OH, a lower alkyl group, or a lower heteroalkyl group;

W represents .alpha. OAc or H;

Q represents H or OH, provided that, when W is .alpha. OAc and Q is OH, Q is .beta.-equatorial;

V represents H or .alpha. OH; and

X represents H or .alpha. OH,

said steroid containing from two to three OH groups.

3. The composition of claim 1 wherein the fusidic acid derivative is in unconjugated form, with D being selected from the group consisting of O.sup.- Na.sup.+, O.sup.- K.sup.+, O.sup.- Rb.sup.+ and O.sup.- Cs.sup.+.

4. The composition of claim 1 wherein D is a covalently linked organic group which contains at least one carbon atom.

5. The composition of claim 4 wherein the covalently linked organic group is an amino acid containing an ionic function which is dissociated within the range of about pH 2 to about pH 12.

6. The composition of claim 5 wherein the amino acid is selected from the group consisting of glycine, taurine, homoglycine and homotaurine.

7. The composition of claim 5 wherein the amino acid is selected from the group consisting of sulfobetaine and phosphobetaine.

8. The composition of claim 4 wherein the covalently linked organic group is a peptide of two to three amino acids, said peptide containing an ionic function which is dissociated within the range of about pH 2 to about pH 12.

9. The composition of claim 8 wherein the peptide is selected from the group consisting of diglycine and glutathione.

10. The composition of claim 8 wherein the peptide is selected from the group consisting of sarcosylcysteine, hydroxyprolinetaurine, and sarcosyltaurine.

11. The composition of claim 4 wherein the covalently linked organic group is a heteroalkyl group of about three or fewer carbon atoms, said group containing an ionic function which is dissociated within the range of about pH 2 to about pH 12.

12. The composition of claim 4 wherein the covalently linked organic group is a uronic acid of about six or fewer carbon atoms, said uronic acid containing an ionic function which is dissociated within the range of about pH 2 to about pH 12.

13. The composition of claim 4 wherein the covalently linked organic group is a polyether containing between about six and about fourteen carbon atoms, inclusive, said polyether terminating in an ionic function which is dissociated within the range of about pH 2 to about pH 12.

14. The composition of claim 4 wherein the covalently linked organic group is a polyether containing between about sixteen and about twenty-four carbon atoms, inclusive.

15. The composition of claim 4 wherein the covalently linked organic group is a polyether containing between about sixteen and about twenty-four carbon atoms, inclusive, said polyether terminating in an ionic function which is dissociated within the range of about pH 2 to about pH 12.

16. The composition of claim 4 wherein the covalently linked organic group is bonded to C.sub.21 of the fusidic acid derivative by an amide or an ester linkage.

17. The composition of claim 4 wherein the covalently linked organic group contains an ionic function, said ionic function being SO.sub.3.sup.-, SO.sub.4.sup.-, or COO.sup.-.

18. The composition of claim 2 wherein the fusidic acid derivative is further characterized in that

(a) its unconjugated derivative is retained on a column for a length of time sufficient to produce a k' factor value of at least about 4, said k' factor value being obtained by subjecting a monomeric solution of 1 mg/ml of such unconjugated derivative to high-performance (3,000 psi) liquid column chromatography using a 250.times.4.6 mm column having octadecylsilane-coated 5 .mu.m silica particles as the stationary phase and a mobile phase, delivered at 1.0 ml/min., consisting of 75% methanol in water, v/v, buffered with 0.005 M KHHD 2PO.sub.4 /H.sub.3 PO.sub.4 to give an apparent pH value, as measured using a glass electrode, of pH 5.0, said k' factor value being defined by ##EQU2## where t.sub.0 is the retention time in said column of the solvent front and t.sub.r is the retention time in said column of said unconjugated derivative as measured by obtaining the elution profile of said fusidic acid derivative by absorbance at 210 nm;

(b) the critical micellar temperature of an aqueous 1% solution, w/v, of the steroid is below about 37.degree. C. within the range of about pH 2 to about pH 12; and

(c) the critical micellar concentration of the steroid is less than about 8 mMolar in 0.15M NaCl at 37.degree. C., as measured by surface tension.

19. The composition of claim 18 wherein the critical micellar temperature of the fusidic acid derivative is below about 20.degree. C. and the critical micellar concentration is less than about 4 mMolar.

20. The composition of claim 1 wherein the adjuvant is an ionized or partially ionized, water-soluble alkali salt of a fusidic acid or a derivative thereof.

21. A composition useful for the prevention or treatment of a human or animal disorder or for the regulation of a human or animal physiological condition comprising, in admixture:

(a) as an active ingredient, a biologically-effective amount of a peptide specific for the disorder or condition;

(b) as an adjuvant, an ionized or partially ionized, water-soluble alkali salt of cephalosporin P.sub.1, P.sub.2, P.sub.3, P.sub.4 or P.sub.5 or a derivative thereof, said cephalosporin or derivative being capable of increasing peptide permeability of a human or animal mucosal surface across which the peptide is to be administered, in an amount effective to increase the permeability of said mucosal surface to said peptide.

22. The composition of claim 20 wherein the derivative of fusidic acid is 24,25-dihydrofusidic acid.

23. The composition of claim 20 wherein the derivative of fusidic acid is 17,20-24,25-tetrahydrofusidic acid.

24. The composition of claim 20 wherein the derivative of fusidic acid is 3-acetoxyl-fusidic acid.

25. The composition of claim 20, 22, 23 or 24 wherein the fusidic acid or derivative thereof is conjugated at C.sub.21.

26. The composition of claim 21 wherein the cephalosporin or derivative is conjugated at C.sub.21.

27. The composition of claim 20 wherein the derivative of fusidic acid is tauro-24,25-dihydrofusidate.

28. The composition of claim 20 wherein the derivative of fusidic acid is tauro-16.alpha.-OH-17,20-24,25-tetrahydrofusidate.

29. The composition of claim 20 wherein the derivative of fusidic acid is tauro-16.alpha.-OH-24,25-dihydrofusidate.

30. The composition of claim 20 wherein the derivative of fusidic acid is tauro-17,20-24,25-tetrahydrofusidate.

31. The composition of claim 20 wherein the derivative of fusidic acid is glyco-24,25-dihydrofusidate.

32. The composition of claim 20 wherein the derivative of fusidic acid is tauro-16-O-methyl-ether-24,25-dihydrofusidate.

33. The composition of claim 20 wherein the derivative of fusidic acid is tauro-16-O-methyl-ether-17,20-24,25-tetrahydrofusidate.

34. The composition of claim 1, 20 or 21 wherein said peptide has a molecular weight between about 100 and about 300,000 daltons.

35. The composition of claim 1, 20 or 21 wherein said peptide is a hormone or a precursor or inhibitor thereof.

36. The composition of claim 1, 20 or 21 wherein said peptide is an enzyme or a precursor or an inhibitor thereof.

37. The composition of claim 34 wherein said peptide is a glycoprotein.

38. The composition of claim 1, 20 or 21 wherein said peptide is selected from the group consisting of proinsulin glucagon, parathyroid hormone, parathyroid hormone antagonist, calcitonin, vasopressin, renin, prolactin, growth hormone, thyroid stimulating hormone, corticotropin, corticotropin-releasing factor, follicle stimulating hormone, luteinizing hormone, chorionic gonadotropin, atrial peptides, interferon, tissue plasminogen activator, gammaglobulin, Factor VIII, growth hormone releasing hormone, luteinizing hormone releasing hormone and somatostatin.

39. The composition of claim 35 wherein the hormone is glucagon.

40. The composition of claim 35 wherein the hormone is human chorionic gonadotropin.

41. The composition of claim 35 wherein the hormone is corticotropin-releasing factor.

42. A composition useful for regulating blood glucose and free fatty acid levels comprising, in admixture:

(a) as an active ingredient, a medically-effective amount of glucagon; and

(b) as an adjuvant, an effective amount of a salt of tauro-24,25-dihydrofusidate.

43. A composition useful for affecting human pregnancy comprising, in admixture:

(a) as an active ingredient, a medically-effective amount of human chorionic gonadotropin; and

(b) as an adjuvant, an effective amount of a salt of tauro-24,25-dihydrofusidate.

44. A composition useful for regulating adrenocorticotropin synthesis and release comprising, in admixture:

(a) as an active ingredient, a medically-effective amount of corticotropin-releasing hormone; and

(b) as an adjuvant, an effective amount of a salt of tauro-24,25-dihydrofusidate.

45. The composition of claim 42, 43, or 44 wherein the salt is a sodium salt.

46. A pharmaceutical preparation suitable for use as a nasal spray or nose drops comprising a solution or suspension of the composition of claim 1, 20, 21, 42, 43, or 44 in a physiologically acceptable carrier.

47. The pharmaceutical preparation of claim 46 wherein the physiologically acceptable carrier is a sodium phosphate buffer, a sodium phosphate buffered sodium chloride solution, or a sodium chloride solution.

48. A pharmaceutical preparation suitable for use as eye drops comprising a solution or suspension of the composition of claim 1, 20, 21 or 42 in a physiologically acceptable carrier.

49. A pharmaceutical preparation in the form of a nasal spray or nose drops useful for the treatment of diabetes comprising a solution or suspension in a physiologically buffered sodium chloride solution of an admixture of a medically-effective amount of insulin as active ingredient and an effective amount of sodium tauro-24,25-dihydrofusidate as adjuvant.

50. In a method of administering a peptide which comprises applying to a human or animal mucosal surface for absorption across said body surface a composition comprising, as an active ingredient, a peptide specific for a disorder or condition, the improvement which comprises: applying the peptide to the mucosal surface in admixture with biocompatible, water-soluble, fusidic acid derivative which has the formula: ##STR5## wherein a dashed line represents a single or a double bond; D represents a group having a molecular weight below about 600 daltons which renders an effective amount of said steroid water-soluble within a range of about pH 2 to about pH 12;

E and G each represent OAc, OH, a lower alkyl group or a lower heteroalkyl group;

W represents OAc or H; and

Q, V and X each represent H or OH, said steroid containing from two or three polar functions, exclusive of the function represented by D; which biocompatible, water-soluble fusidic acid derivative acts an adjuvant being capable of increasing peptide permeability of the human or animal muscosal surface across which the peptide is to be administered, in an amount effective to increase the permeability of said mucosal surface to said peptide.

51. The method of claim 50 wherein the mucosal surface is a nasal mucosal surface.

52. The method of claim 50 wherein the mucosal surface is a conjunctival surface.

53. The method of claim 50 wherein the mucosal surface is an oropharyngeal, nasopharyngeal or respiratory tract surface.

54. The method of claim 50 wherein the mucosal surface is a vaginal, cervical or endometrial surface.

55. The method of claim 50 wherein the mucosal surface is a rectal, colonic, gastric or intestinal surface.

56. The method of claim 50 wherein the mucosal surface is a urethral or urinary bladder surface.

57. The method of claim 50 wherein the human or animal body surface is an ear canal or tympanic membrane surface.

58. The method of claim 50 wherein the composition is applied in the form of a nasal spray or nose drops.

59. The method of claim 50 wherein the composition is applied in the form of eye drops.

60. The method of claim 50 wherein the composition is applied in the form of a suppository.

61. The method of claim 50 wherein the composition is applied in the form of a spray, salve, ointment or cream.

62. The method of claim 50 wherein the drug is a peptide.

63. The method of claim 50 wherein the peptide is a hormone or a precursor or inhibitor thereof.

64. The method of claim 63 wherein the hormone is selected from the group consisting of proinsulin, glucagon, parathyroid hormone, calcitonin, vasopressin, renin, prolactin, growth hormone, thyroid stimulating hormone, corticotropin, corticotropin-releasing factor, follicle stimulating hormone, luteinizing hormone, growth hormone releasing hormone, luteinizing hormone releasing hormone and somatostatin or an antagonist thereof.

65. The method of claim 50 wherein the peptide is selected from the group consisting of interferon, tissue plasminogen activator, atrial peptides, natriuretic peptide, gammaglobulin and Factor VIII.

66. The method of claim 50 wherein the peptide is a glycoprotein.

67. The method of claim 66 wherein the glycoprotein is chorionic gonadotropin.

68. A method of administering glucagon for the regulation of blood glucose and free fatty acid levels which comprises applying to a nasal mucosal surface for absorption across said surface the composition of claim 66 formulated as a nasal spray or nose drops.

69. A method of administering human chorionic gonadotropin which comprises applying to a nasal mucosal surface for absorption across said surface the composition of claim 43 formulated as a nasal spray or nose drops.

70. A method of administering corticotropin-releasing factor which comprises applying to a nasal mucosal surface for absorption across said surface the composition of claim 44 formulated as a nasal spray or nose drops.

71. A method of administering a vaccine to a human being or animal to immunize said human being or animal against a particular disease which comprises applying to a human or animal mucosal surface for absorption across said muscosal surface a composition comprising, in admixture:

(a) as a vaccinating agent, a biologically-effective amount of a peptide antigen or fragment thereof, said peptide antigen or fragment thereof, said peptide antigen being capable of eliciting an immune response protective against the particular disease; and

(b) as an adjuvant, a biocompatible, water-soluble, fusidic acid derivative which has the formula: ##STR6## wherein a dashed line represents a single or a double bond; D represents a group having a molecular weight below about 600 daltons which renders an effective amount of said steroid water-soluble within a range of about pH 2 to about pH 12;

E and G each represent OAc, OH, a lower alkyl group or a lower heteroalkyl group;

W represents OAc or H; and

Q, V and X each represent H or OH, said steroid containing from two to three polar functions, exclusive of the function represented by D;

said adjuvant being capable of increasing peptide antigen permeability of a human or animal mucosal surface across which the peptide is to be administered, in an amount effective to increase the permeability of said mucosal surface to said peptide.

72. The method of claim 50 wherein the composition is applied in a long term release dosage form.

73. The method of claim 72 wherein the long term release dosage form is a slow, continuous or intermittent form.

74. The method of claim 72 wherein the long term release dosage form is selected from the group consisting of a polymer form, a microcapsule form, a microsphere form, an osmotic diffusion device or a membrane release device.

75. The method of claim 50 in which the biocompatible, water-soluble, fusidic acid derivative is an ionized or partially ionized, water-soluble alkali salt of fusidic acid or a derivative thereof.

76. The method of claim 50 in which the biocompatible, water-soluble, fusidic acid derivative is an ionized or partially ionized, water-soluble alkali salt of cephalosporin P.sub.1, P.sub.2, P.sub.3, P.sub.4 or P.sub.5 or a derivative thereof.

Details for Patent 4,746,508

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 004 1975-06-26 ⤷  Try it Free Beth Israel Hospital Assn. (Boston, MA) The Brigham and Womens Hospital, Inc. (Boston, MA) 2039-02-26 RX search
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 006 1975-06-26 ⤷  Try it Free Beth Israel Hospital Assn. (Boston, MA) The Brigham and Womens Hospital, Inc. (Boston, MA) 2039-02-26 RX search
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 007 1975-06-26 ⤷  Try it Free Beth Israel Hospital Assn. (Boston, MA) The Brigham and Womens Hospital, Inc. (Boston, MA) 2039-02-26 RX search
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 009 1975-06-26 ⤷  Try it Free Beth Israel Hospital Assn. (Boston, MA) The Brigham and Womens Hospital, Inc. (Boston, MA) 2039-02-26 RX search
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 010 1975-06-26 ⤷  Try it Free Beth Israel Hospital Assn. (Boston, MA) The Brigham and Womens Hospital, Inc. (Boston, MA) 2039-02-26 RX search
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 011 1975-06-26 ⤷  Try it Free Beth Israel Hospital Assn. (Boston, MA) The Brigham and Womens Hospital, Inc. (Boston, MA) 2039-02-26 RX search
Bel Mar CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017054 001 1974-03-26 ⤷  Try it Free Beth Israel Hospital Assn. (Boston, MA) The Brigham and Womens Hospital, Inc. (Boston, MA) 2039-02-26 DISCN search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Baxter
Colorcon
Dow
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.